Published in Drug Week, November 23rd, 2001
This data was presented at the 66th Annual Scientific Meeting of the American College of Gastroenterology held in Las Vegas, Nevada, October, 2001.
CuraGen's CG53135 may have potential advantages over existing therapies for inflammatory bowel disease. Currently marketed drugs do not act directly to prevent the colon tissue damage present in patients diagnosed with this debilitating disease. In contrast, through its proliferative response on epithelial and mesenchymal cells,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.